November 2007
- New views of receptor molecule may open doors New Haven, Conn., July 26, 2007 — High resolution views of a receptor molecule that is implicated in cancer offer a clear target for the development of a new class of cancer drugs, Yale School of Medicine researchers report July 27 in Cell.
- Compassionate use process is not so compassionate by Judi Lifton Judi Lifton had no idea what she was getting into when she tried to get compassionate use of AMN107 for her partner, Leland Emerson. He could not qualify for the trial as he had already taken Gleevec, Sutent and AMG706. Being ever the vigilant caregiver, Judi began the process which would end up consuming all of her time and possibly her sanity.
- Looking for new ways to fight GIST by Jerry Call In 1991, Joseph Schlessinger, PhD, and Axel Ullrich, PhD, co-founded a small bio-tech company. Taking the first letter of each of their names, they named the company Sugen. Sugen was considered to be one of the early pioneers in the signal transduction field. Many Life Raft Group members will recognize the name Sugen. It is what GIST patients called the experimental drug SU11248 before it had a real name. SU11248 was a mouthful, so patients made up their own name, Sugen, named after the drug manufacturer.
- November 2007 U.S. clinical trial update by Jim Hughes
- November 2007 U.S. clinical trial update by Jim Hughes